


IgA Nephropathy Market Report 2032: Epidemiology Data, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

IgA Nephropathy companies are Calliditas Therapeutics AB, Traveře Therapeutics, Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, and more.

LAS VEGAS, NEVADA, UNITED STATES, June 5, 2024 /EINPresswire.com/ -- DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and China.



To Know in detail about the IgA Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [IgA Nephropathy Market Forecast](#)

Some of the key facts of the IgA Nephropathy Market Report:

The IgA Nephropathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

In 2022, the IgA Nephropathy Market Size was the highest in the US among the 7MM, accounting for approximately USD 160 million, which is further estimated to increase by 2032.

Calliditas Therapeutics' TARPEYO was the first FDA-approved treatment for IgA Nephropathy, which the US FDA approved in December 2021, and the drug entered the market by the end of January 2022.

Most IgA Nephropathy patients are diagnosed accidentally; the disease is mostly diagnosed during routine checkups.

In February 2023, Traveře Therapeutics' dual endothelin angiotensin receptor antagonist FILSPARI, became the first non-immunosuppressive FDA-approved treatment for IgA Nephropathy, although still being put on REMS due to its potential hepatotoxic and embryo-fetal

toxic effects.

The total IgA Nephropathy prevalent cases of in the 7MM and China were ~1,899,000 cases in 2022 and are projected to increase during the forecast period (2023–2032).

The total number of IgA Nephropathy prevalent cases in the United States was around ~193,700 cases in 2022.

Among the EU4 countries, Germany accounted for the largest IgA Nephropathy cases, followed by France, whereas Spain accounted for the lowest number of prevalent cases in 2022.

According to DelveInsight estimates, there were ~1,414,000 prevalent cases of IgA Nephropathy in China in 2022, and the prevalence is projected to increase during the forecast period.

Japan accounted for about 88,000 diagnosed prevalent cases of IgA Nephropathy in 2022.

The expected launch of Narsoplimab (Omeros Corporation) in 2024 is set to bring major changes in the treatment landscape of IgA Nephropathy, bringing in safer and more effective treatment options for IgA Nephropathy patients.

The recently published Part B results of the Phase III trial are expected to grant complete approval to TARPEYO, further increasing its availability to IgA Nephropathy patients, but its comparatively high cost still possesses a barrier.

Key IgA Nephropathy Companies: Calliditas Therapeutics AB, Travele Therapeutics Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics Inc., Vera Therapeutics Inc., Otsuka Pharmaceutical, and others

Key IgA Nephropathy Therapies: TARPEYO/ KINPEYGO (budesonide), Narsoplimab, and others

The IgA Nephropathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgA Nephropathy pipeline products will significantly revolutionize the IgA Nephropathy market dynamics.

IgA Nephropathy Overview

IgA Nephropathy, also known as Berger's disease, is a chronic kidney disorder characterized by the deposition of Immunoglobulin A (IgA) in the glomeruli, which are the filtering units of the kidneys. This condition leads to inflammation and damage of the glomeruli, affecting their ability to function properly. IgA Nephropathy is a form of glomerulonephritis, which refers to inflammation of the glomeruli.

IgA Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

IgA Nephropathy Epidemiology Segmentation:

The IgA Nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of IgA Nephropathy

Prevalent Cases of IgA Nephropathy by severity

Gender-specific Prevalence of IgA Nephropathy

Diagnosed Cases of Episodic and Chronic IgA Nephropathy

Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ [IgA Nephropathy Epidemiology Forecast](#)

IgA Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy market or expected to get launched during the study period. The analysis covers IgA Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the IgA Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

IgA Nephropathy Key Companies

Calliditas Therapeutics AB, Travele Therapeutics Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics Inc., Vera Therapeutics Inc., Otsuka Pharmaceutical

IgA Nephropathy Therapies

TARPEYO/ KINPEYGO (budesonide), Narsoplimab, and others.

Discover more about therapies set to grab major IgA Nephropathy market share @ [IgA Nephropathy Treatment Landscape](#)

IgA Nephropathy Market Outlook

The primary approach in managing IgA Nephropathy focuses on comprehensive supportive care, encompassing strategies to control blood pressure, minimize proteinuria, mitigate lifestyle risk factors, and reduce general kidney stress. The efficacy of immunosuppressive therapies is a

subject of debate. If considered, a regimen of high-dose systemic corticosteroids for a limited duration might be an option, carefully weighed against patient-specific factors that could contraindicate such treatment. It's important to note that as glomerular filtration rate (GFR) declines, the adverse effects associated with corticosteroid treatment significantly escalate. Beyond corticosteroids, there's limited evidence supporting the benefit of additional immunosuppressive agents, with mycophenolate mofetil being a notable exception in Asian patients.

Key players in the IgA Nephropathy therapeutic market include Calliditas Therapeutics AB, Chinook Therapeutics, Inc., Novartis Pharmaceuticals, Omeros Corporation, Otsuka Pharmaceutical, RemeGen, Vera Therapeutics, and others.

Calliditas' TARPEYO/KINPEYGO (budesonide) delayed-release capsules marked the first FDA-approved treatment for IgA Nephropathy. Indicated for patients with a urine protein-to-creatinine ratio (UPCR) of 1.5 g/g or higher, it was granted accelerated approval by the US FDA in December 2021, underscoring the urgent need for safe and effective treatments.

FILSPARI (sparsentan), developed by Traveo Therapeutics/Vifor Pharma, is poised to enter the IgA Nephropathy treatment arena through an accelerated approval pathway in February 2023. Sparsentan represents a novel, orally active compound that acts as a potent dual antagonist of the ETA and AT1 receptors, implicated in the progression of kidney disease. Its accelerated clearance was based on preliminary results from the pivotal Phase III PROTECT study. The EMA has also accepted the CMA application, with a review decision expected in the second half of 2023.

Several promising therapies are in the pipeline, aiming to address the unmet needs for disease-specific, targeted treatments and innovative mechanisms of action in IgA Nephropathy. These include narsoplimab (Omeros Corporation), atrasentan (Chinook Therapeutics), iptacopan (Novartis Pharmaceuticals), sibeprenlimab (Otsuka Pharmaceutical), cemdisiran (Alnylam Pharmaceuticals/Regeneron Pharmaceuticals), and telitacicept (RemeGen (Chinook Therapeutics)).

In summary, while there are currently only two FDA-approved treatments for IgA Nephropathy, recent drug approvals offer new therapeutic options. However, the demand for more effective and targeted therapies remains high. The therapeutic landscape for IgA Nephropathy is expected to see substantial shifts with the introduction of novel therapies and a robust pipeline of drugs in development.

Scope of the IgA Nephropathy Market Report:

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan and China]

Key IgA Nephropathy Companies: Calliditas Therapeutics AB, Travele Therapeutics Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics Inc., Vera Therapeutics Inc., Otsuka Pharmaceutical, and others

Key IgA Nephropathy Therapies: TARPEYO/ KINPEYGO (budesonide), Narsoplimab, and others

IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies

IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

IgA Nephropathy Unmet Needs, KOL's views, Analyst's views, IgA Nephropathy Market Access and Reimbursement

Table of Contents:

1. IgA Nephropathy Market Report Introduction
2. Executive Summary for IgA Nephropathy
3. SWOT analysis of IgA Nephropathy
4. IgA Nephropathy Patient Share (%) Overview at a Glance
5. IgA Nephropathy Market Overview at a Glance
6. IgA Nephropathy Disease Background and Overview
7. IgA Nephropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of IgA Nephropathy
9. IgA Nephropathy Current Treatment and Medical Practices
10. IgA Nephropathy Unmet Needs
11. IgA Nephropathy Emerging Therapies
12. IgA Nephropathy Market Outlook
13. Country-Wise IgA Nephropathy Market Analysis (2019–2032)
14. IgA Nephropathy Market Access and Reimbursement of Therapies
15. IgA Nephropathy Market Drivers
16. IgA Nephropathy Market Barriers
17. IgA Nephropathy Appendix
18. IgA Nephropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

IgA Nephropathy Pipeline

"IgA Nephropathy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the IgA Nephropathy

market. A detailed picture of the IgA Nephropathy pipeline landscape is provided, which includes the disease overview and IgA Nephropathy treatment guidelines.

IgA Nephropathy Epidemiology

DelveInsight's 'IgA Nephropathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted IgA Nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/717464522>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.